
    
      This is a 2 year, open label trial to evaluate the role of rapamycin as treatment for ADPKD.
      Patients will be randomized 2:1 to the rapamycin arm or to standard therapy. The dose of
      rapamycin will be adjusted so that patients obtain 24 trough levels of 4-6ng/ml. There will
      be a volumetric MRI measurement at the start and end of the treatment period. Patients will
      be monitored every 4 months throughout the study.
    
  